SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-165886
Filing Date
2024-06-21
Accepted
2024-06-21 17:21:00
Documents
13
Period of Report
2024-06-21
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d891172d8k.htm   iXBRL 8-K 34892
  Complete submission text file 0001193125-24-165886.txt   153511

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA avir-20240621.xsd EX-101.SCH 2859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20240621_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20240621_pre.xml EX-101.PRE 10818
16 EXTRACTED XBRL INSTANCE DOCUMENT d891172d8k_htm.xml XML 3502
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 241061423
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)